The United States Patent and Trademark Office has issued U.S. Patent No. 9,618,476 to Nanomedical Diagnostics, a biotech company pioneering label-free graphene biosensors for use in drug discovery. The patent covers any holistic graphene biosensor system that detects biomolecular interactions and is a foundational patent behind the company’s AGILE R100 platform.
“This patent showcases our company commitment to bringing cutting-edge nanotechnology to the life science world,” says Nanomedical Diagnostics founder and CTO, Dr. Brett Goldsmith, also the inventor named on the patent. “Graphene biosensors solve many problems encountered with current sensing tools and enable capabilities that aren’t possible with existing techniques. We are committed to developing graphene biosensors into sensitive measurement tools that help biomedical researchers make confident decisions earlier. The issuance of this patent demonstrates that.”
The patent issue highlights the achievement of the Nanomedical Diagnostics technology team in developing a novel approach for label-free detection of biomolecular interactions. The ability to leverage graphene biosensors in a user-friendly, complete system enables sensitivity, small sample sizes, portability, and ease of use that open new applications in the fields of drug discovery, disease diagnostics, health monitoring, and biomanufacturing.
AGILE R100 is available for commercial sale, for research use only.
Graphene Entrepreneur is a division of the National Graphene Association. The Mission of the NGA is to bring together current and future graphene stakeholders — entrepreneurs, companies, researchers, developers and suppliers, investors, venture capitalists and government agencies — to drive innovation, and to promote and facilitate the commercialization of graphene products and technologies in the United States.
For questions or comments please email us at firstname.lastname@example.org.